1019201-53-6

Basic information

• Product Name: 2-(trifluoroMethyl)isonicotinoyl chloride
• Synonyms: 2-(trifluoroMethyl)isonicotinoyl chloride
• CAS NO: 1019201-53-6
• Molecular Formula: C₇H₃ClF₃NO
• Molecular Weight: 209.5530296
• Mol File: 1019201-53-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(trifluoroMethyl)isonicotinoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(trifluoroMethyl)isonicotinoyl chloride(1019201-53-6)
• EPA Substance Registry System: 2-(trifluoroMethyl)isonicotinoyl chloride(1019201-53-6)

Safety Data

• Hazardous Substances Data: 1019201-53-6(Hazardous Substances Data)

Usage

Molecular weight

201.55 g/mol
Derivative of isonicotinoyl chloride
Used in organic synthesis and as a reagent for introducing the isonicotinoyl group into various compounds
Trifluoromethyl substituent makes it useful in pharmaceutical and agrochemical applications
Reactive compound
Handled and stored under inert gas to avoid exposure to air or moisture
Potential for generating toxic or corrosive byproducts
Important in medicinal chemistry and drug development
Valuable in the synthesis of biologically active molecules

Upstream product

• 131747-41-6 2-(trifluoromethyl)-4-pyridinecarboxylic acid 

Downstream Products

• 916210-02-1 2-(trifluoromethyl)pyridine-4-carbonitrile 

Relevant articles and documents

Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and in Vivo Activity of an Oxadiazole Series

The gene KCNT1 encodes the sodium-activated potassium channel KNa1.1 (Slack, Slo2.2). Variants in the KCNT1 gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders in infants and children, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Effective treatment options for KCNT1-related disease are absent, and novel therapies are urgently required. We describe the development of a novel class of oxadiazole KNa1.1 inhibitors, leading to the discovery of compound 31 that reduced seizures and interictal spikes in a mouse model of KCNT1 GoF.

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that 13an could be a promising drug candidate for the treatment of TNBC and hence merits further studies.